Induced Pluripotent Stem Cells Production Market Competitive Landscape: Key Players Identified

 The global induced pluripotent stem cells production market size is expected to reach USD 2.76 billion by 2030, registering a CAGR of 9.44% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increase in demand for induced pluripotent stem cells (iPSCs) in comparison to Embryonic Stem Cells (ESCs) has offered a significant drive to the market. Advantages such as no stem cell-related ethical issues, personalized treatment, and flexibility during cell-based research have created a favorable scenario for market growth. In addition, the prevalence of chronic disorders is also driving the growth of the induced pluripotent stem cells production market, as conditions like heart disease, stroke, diabetes, and many more can be treated by utilizing iPSCs-mediated therapy. For example, according to the International Diabetes Federation (IDF), 537 million people are already living with diabetes in 2021.

The rising research activities during COVID-19 pandemic have positively impacted the market. The pandemic fueled research in many fields as the SARS CoV-2 infection resulted in many diseases in the patients. For instance, in April 2021, researchers from USA stated that up to 25% of COVID-19 patients suffered cardiac dysfunction. Through their research article, they demonstrated the pathogenesis via exposure of iPSCs-derived cardiac cells to SARS CoV-2, and similar alterations were confirmed from human autopsy specimens of the patients. Such insights allow the use of induced pluripotent stem cells (iPSCs) as drug or therapy development platforms and their utilization in the management of the long-term effects of COVID-19.

Gather more insights about the market drivers, restrains and growth of the Global Induced Pluripotent Stem Cells Production Market

Induced pluripotent stem cells are cells that are derived from adult somatic cells and then further reprogrammed to obtain the pluripotency as that of ESCs. These iPSCs are proving to be an ethically uncomplicated alternative for research that involves ESCs. The derivation of the ESCs is associated with the destruction of an embryo at the blastocyte stage, which has led to a maximum number of ethical debates. However, induced pluripotent stem cells have solved the ethical issue over the destruction of human embryos in research by involving only the genetic reprogramming of somatic cells. This has propelled the market growth and resulted in numerous applications including drug discovery, disease modeling, toxicology testing, and many others. For instance, in August 2021, Fate Therapeutics announced the treatment of the first patient with FT819 during clinical trials. FT819 is an engineered CAR-T cell therapy that is derived from iPSCs. Also, the rising focus of the research community on exploring applications of induced pluripotent stem cells in regenerative medicine due to their unique characteristics such as differential potential, self-renewable, immunomodulatory properties, and others; is set to drive the market expansion.

 

Induced Pluripotent Stem Cells Production Market Report Highlights

  • By process, the manual iPSC production process segment dominated the market and accounted for the largest revenue share in 2023.
  • By workflow, the cell culture segment dominated the market with the largest revenue share of 37.34% in 2023. Cell culture workflow is inclusive of revenues generated from iPSC harvest products, expansion products, and differentiation products; thus contributing to the market relevance of this segment.
  • By product, the consumables and kits segment dominated the market and accounted for the largest revenue share of 40.32% in 2023. The never-ceasing research and development activities in the iPSCs space are driving the demand for various consumables & kits.
  • By application, drug development & discovery segment dominated the market with the largest revenue share of 43.33% in 2023.
  • By end-user, the biotechnology and pharmaceutical companies segment dominated the market with the largest revenue share of 59.35% in 2023. The availability and adoption of various kits, consumables, and instruments along with iPSCs products are driving the revenue generation in this segment.
  • North America dominated the market and accounted for the largest revenue share of 40.98% in 2023. The growing incidence of chronic diseases in this region, developed healthcare infrastructure, funds from private & government initiatives, and strategic business models are driving the revenue generation in the marketspace.

List of Key Players in Induced Pluripotent Stem Cells Production Market

  • Lonza
  • Axol Bioscience Ltd.
  • Evotec
  • Hitachi, Ltd.
  • REPROCELL Inc.
  • Merck KGaA
  • REPROCELLS, Inc.
  • Fate Therapeutics
  • Thermo Fisher Scientific, Inc.
  • StemCellsFactory III
  • Applied StemCells, Inc.

Order a free sample PDF of the Induced Pluripotent Stem Cells Production Market Intelligence Study, published by Grand View Research.

Comments

Post a Comment

Popular posts from this blog

Drug Addiction - Pipeline Review, H1 2017 Market Overview and trends research report

Radiant insights, inc latest Pharmaceutical and Healthcare disease pipeline guide Drug Addiction - Pipeline Review, H1 2017, provides an overview of the Drug Addiction (Central Nervous System) pipeline landscape. Drug addiction, also called substance dependence or chemical dependency, is a disease that is characterized by a destructive pattern of drug abuse that leads to significant problems involving tolerance to or withdrawal from the substance. Drug addiction symptoms or behaviors include recurrent drug use that results in a lack of meeting important obligations at work, school, or home, inability to sleep, awake at unusual times, unusual laziness, loss of or increased in appetite, changes in eating habits, cold, sweaty palms; shaking hands., red, watery eyes; pupils larger or smaller than usual and unusual smells on breath, body or clothes. Report Highlights Radiant insights, inc Pharmaceutical and Healthcare latest pipeline guide Drug Addiction - Pipeline Review, H1 2017, p...
Read more

All Countries Dialyzer Industry 2013-2028 - Market Size, Share, Outlook, Growth, Key Players and Forecast

The global Dialyzer market was valued at $XX million in 2018, and Radiant Insights, Inc analysts predict the global market size will reach $XX million by the end of 2028, growing at a CAGR of XX% between 2018 and 2028. This report provides detailed historical analysis of global market for Dialyzer from 2013-2018, and provides extensive market forecasts from 2019-2028 by region/country and subsectors. It covers the sales volume, price, revenue, gross margin, historical growth and future perspectives in the Dialyzer market. Download Free Sample Report @ https://www.radiantinsights.com/research/2013-2028-report-on-global-dialyzer-market/request-sample Leading players of Dialyzer including: • Fresenius Medical Care • Baxter • Nipro • Asahi Kasei • Toray • B.Braun • Nikkiso • Medtronic • Kawasumi • Medica • Wego • Lengthen • Peony Medical • Chengdu OCI • Bain Medical Equipment Market split by Type, can be divided into: • Flat Type Dialyzer • Coil Tube Dialyzer • Ho...
Read more

Insights into the Medical Waste Disposal Category: A Comprehensive Procurement Intelligence Report

  Medical Waste Disposal Category Overview The medical waste disposal category is anticipated to grow at a CAGR of 6.0% from 2023 to 2030. Appropriate disposal of medical trash is the key challenge for healthcare providers across the globe. Rising awareness about the benefits of proper medical waste management for treatment, recycling, and disposal of medical trash has boosted the growth of the category. According to the World Health Organization Study Report 2022, countries with low income generate over 0.2 kg of medical trash per day per hospital bed, whereas countries with high income generate hazardous waste of up to 0.5 kg per hospital bed each day. Moreover, rising government initiatives and strict rules and regulations for waste management are also expected to drive the category. For instance, in December 2022, an MOU was signed between the Center for Health Environment Research and Development and Can Tho Central General Hospital under USAID’s Reducing Pollution Project. T...
Read more